Royal Bank of Canada initiated coverage on shares of Passage Bio (NYSE:GFL) in a research note published on Monday morning, BayStreet.CA reports. The brokerage issued an outperform rating and a $19.00 price objective on the stock.
A number of other equities research analysts also recently issued reports on the stock. Scotiabank initiated coverage on shares of Passage Bio in a report on Monday. They issued an outperform rating and a $23.00 target price for the company. Barclays initiated coverage on shares of Passage Bio in a report on Monday. They issued an equal weight rating and a $20.00 target price for the company. JPMorgan Chase & Co. started coverage on shares of Passage Bio in a report on Monday. They issued an overweight rating and a $19.00 target price for the company. Bank of America started coverage on shares of Passage Bio in a research note on Monday. They set a neutral rating for the company. Finally, CIBC started coverage on shares of Passage Bio in a research note on Monday. They set a neutral rating and a $27.00 price objective for the company. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company currently has a consensus rating of Buy and an average target price of $21.38.
Shares of NYSE:GFL traded down $0.60 during trading on Monday, reaching $13.14. The stock had a trading volume of 1,366,400 shares, compared to its average volume of 2,322,005. Passage Bio has a fifty-two week low of $13.00 and a fifty-two week high of $17.95.
GFL Environmental Inc operates as a diversified environmental services company in North America. The company offers non-hazardous solid waste management, infrastructure and soil remediation, and liquid waste management services. Its solid waste management business line includes the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste for municipal, residential, and commercial and industrial customers.
Read More: Why are gap-down stocks important?
Receive News & Ratings for Passage Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Passage Bio and related companies with MarketBeat.com's FREE daily email newsletter.